Poxel's Phase III Oral Diabetes Therapy Taken Up By Roivant
France's Poxel has completed the out-licensing of its oral Phase III-ready diabetes therapy, the glimin, imeglimin, that could be transformative for both the biotech and the US and European licensee, Roivant Sciences.
You may also be interested in...
Recent development upheaval in non-alcoholic steatohepatitis has created opportunity for new approaches, and Poxel thinks its AMPK activator may address several NASH-related pathologies.
Biopharma start-ups finally had an increase in financing activity, following three sequential quarters with a decrease. A review of biopharma start-up dealmaking and financing activity from January through March 2018, based on data from Strategic Transactions.
Celgene will pursue "high-impact" indications using Vividion's proteomics technology, while Magenta will use Heidelberg's technology to try to optimize bone marrow transplants.